Orphan drugs are still rare. But innovation is increasing.
In 2013, despite there being around 7000 rare conditions affecting roughly 30 million people in the EU alone, there were only 450 medicines in development for orphan diseases. That figure is growing. UK Prix Galien supports it. Please sir, can we have some more?
Think you’re a rare breed?
Could you be Best in Breed?
The UK Prix Galien Orphan Product Award recognises innovation in the development of drugs to treat rare disease. New products that have been granted Orphan Drug status in the EU and/or the US in the 2-year qualifying period are
eligible for entry. For entry details, including key dates and processes, click here.